WBA $31.94 Walgreens Report
Fourth quarter results ahead of expectations
Raising Long-Term Targets for U.S. Healthcare Segment
Fourth quarter and fiscal year financial highlights
Fourth quarter loss per share* from continuing operations was $0.48, a decrease of $0.89 from the year-ago quarter; adjusted earnings per share (EPS*) decreased 31.8 percent to $0.80, down 30.0 percent on a constant currency basis, reflecting a strong prior year quarter with higher COVID-19 vaccination volumes
Fiscal 2022 EPS from continuing operations was $5.01, an increase of 117.6 percent, compared with $2.30 in the year-ago period; adjusted EPS increased 2.5 percent to $5.04, up 3.4 percent in constant currency
Fourth quarter sales from continuing operations decreased 5.3 percent year-over-year, to $32.4 billion, down 3.2 percent on a constant currency basis, including a 660 basis point impact from the anticipated sales decline at AllianceRx Walgreens
Fiscal 2022 sales from continuing operations increased 0.1 percent to $132.7 billion, up 1.2 percent on a constant currency basis, including a 550 basis point impact from AllianceRx Walgreens
Fiscal 2023 guidance and long-term growth outlook
Expecting fiscal year 2023 adjusted EPS of $4.45 to $4.65 as strong core business growth is more than offset by lapping fiscal year 2022 COVID-19 execution, and currency headwinds
Raising U.S. Healthcare fiscal 2025 sales target to $11 billion to $12 billion, with the segment expected to achieve positive adjusted EBITDA by fiscal year 2024
Increased visibility to the company's long-term growth algorithm, building to low-teens adjusted EPS growth in fiscal year 2025 and beyond
DEERFIELD, Ill., October 13, 2022--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the fiscal year and fourth quarter that ended Aug. 31, 2022.
Chief Executive Officer Rosalind Brewer said:
"WBA has delivered ahead of expectations in the first year of our transformation to a consumer-centric healthcare company. Our resilient business achieved growth while navigating macroeconomic headwinds. Fiscal 2023 will be a year of accelerating core growth and rapidly scaling our U.S. Healthcare business. Our execution to date provides us visibility and confidence to increase the long-term outlook for our next growth engine and reconfirm our path to low-teens adjusted EPS growth. Our strategic actions are unlocking sustainable shareholder value as we simplify the company and continue our journey to being a healthcare leader."
Pray for A Pain Free Day!
